Please provide your email address to receive an email when new articles are posted on . The integration of second-generation anti-vascular endothelial growth factor (VEGF) therapies into treatment ...

BerryDunn, a full-service accounting, tax, and consulting firm, will return for the 20th year to the National Association of Medicaid Directors Fall Conference (NAMD), taking place in National Harbor, ...

Roche (RHHBY) announced new data from two studies on ophthalmology drug Vabysmo (faricimab). Vabysmo is already approved in several countries for people with neovascular or ‘wet’ age-related macular ...

Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action ...

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment. A biosimilar to aflibercept ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment.

Purpose To explore the association between early response of different lesions and the number of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal neovascularization and subretinal hemorrhage and exudation, leading to vision impairment.

Researchers evaluated the efficacy, safety, and durability of the port-delivery system with ranibizumab in real-world patients with neovascular age-related macular degeneration. The port-delivery ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two refills per year, ...

The current example in https://github.com/vtzf/abacus-namd seems to perform AIMD and the Hamiltonian/overlap matrix calculations simultaneously. However, in my case ...

Faricimab demonstrated short-term improvements in visual and anatomical outcomes for nAMD patients switching from other anti-VEGF therapies. The study showed reductions in central macular thickness, ...